Antitumor immunotherapy has notched big wins, but in a small proportion of patients. And one possible explanation for why is that approved immunotherapies are not yet planting their flag on most of the battlefields where tumors and the immune system engage in combat. At the opening AACR 2023 plenary session, Ralph DeNardo celebrated the successes of the current, mostly T-cell-based approaches, but also encouraged his colleagues to think more broadly about the antitumor immunity.
New and updated preclinical data presented at the American Association for Cancer Research annual meeting in Orlando, Fla., by: Accent Therapeutics, Alphamab Oncology, Arais Biotech, Avacta, Biotheryx, Cellectis, Corbus Pharmaceuticals, Corvus Pharmaceuticals, Frontier Medicines, Ikena Oncology, In8bio, Medicenna Therapeutics, Medivir, Parthenon Therapeutics, Pathios Therapeutics, Precigen, Quanta Therapeutics, Sporos Biodiscovery, Strand Therapeutics, Syndevrx, Tempest Therapeutics, Transgene, Vincerx Pharma, Volastra Therapeutics.
HER2 is a member of the epidermal growth factor receptor family that is overexpressed in approximately 20% of breast cancers. Trastuzumab, an anti-HER2 antibody discovered 25 years ago has become the standard of care treatment due to its beneficial results.
Estrogen receptor (ER)-positive breast cancer is among the most prevalent subtypes and is the cause of most of the mortality among breast cancer patients. Endocrine therapy is effective in these cases, but the development of resistance is a fact in many cases.
Researchers from Bright Peak Therapeutics AG presented the discovery and preclinical characterization of a novel first-in-class PD-1/interleukin-18 (IL-18) immunocytokine, BPT-567.
